Company:  BIOXCEL THERAPEUTICS, INC ... (BTAI)
Form Type:  SC 13D
Filing Date:  9/14/2018 
CIK:  0001720893 
Address:  555 LONG WHARF DRIVE 
City, State, Zip:  NEW HAVEN, Connecticut 06511 
Telephone:  203-643-8060 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.74  
Change: 
0.01 (0.18%)  
Trade Time: 
11:31 AM EST  
Market Cap: 
$89.81M
Trade BTAI now with 

© 2018  
Description of Business
BioXcel Therapeutics, Inc., or BTI, is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need. Our two most advanced clinical development programs are BXCL501, a sublingual thin film formulation of the †2a adrenergic receptor agonist dexmedetomidine, or Dex, for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent for treatment of a rare form of prostate cancer and pancreatic cancer.
Register and access this filing in:     
  FORM SC 13D